Free shipping on orders over $95Buy one with 1% offer on sale price
Zoom the image with the mouse
Leukotrienes: New Concepts and Targets for Therapy
ISBN:
9789401060455
List Price:
$169.99
Share:
Special Offers Available
Free shipping on orders over $95Buy one with 1% offer on sale priceBuy New
We can help you leverage the power of books
Customer Service
Connect with a dedicated account manager who is there every step of the way.
Price Match Guarantee
If you see better pricing elsewhere on your desired quantity, we will price match so you can be sure to get the best pricing.
Free Shipping
Enjoy free ground shipping on your order of $95 or more!
Brand New Guarantee
We only sell books that are brand new and protect that with a guarantee.
Customization
From author signatures to marketing inserts, custom packaging to brand stickers, we can help take your book marketing to the next level.
Details
In the two decades since the elusive "slow reacting substance of anaphylaxis" (SRS-A) was identified as a product of the action of the 5-lipoxygenase enzyme on arachidonic acid, it has been well established that the leukotrienes are key mediators of both alIergy and inflammation. Their release by alIergen or other challenge has been demonstrated in the lungs of asthmatic subjects, and measurement of urinary leukotriene concentrations in such patients has been shown to be a valuable, non invasive indicator. Significant progress has been made towards the characterization of the leukotriene receptor subtypes, exemplified by the cloning of the LTB4 receptor earlier this year. Coupled with this there has been a continued elucidation of signal transduction mechanisms underlying receptor activation. Consequent upon these advances has been the development of potent antagonists of the CysLT receptor, J and both these and inhibitors of leukotriene biosynthesis have entered clinical practice in the therapy of asthma. In this clinical setting antagonists of the CysLTJ receptor have been shown to be an effective therapy in chronic asthmatics, against antigen- and exercise-induced bronchoconstriction, and in aspirin-intolerant asthmatics. The advent of this new class of agents promises to change the way in which asthmatic patients are currently treated.
Product details
Need Books? Bookpal makes it easy
Connect With Us
Customer Reviews
Products related to this item
Related Products